TG Therapeutics, Inc. cash flow to debt ratio of -9.50% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

TG Therapeutics, Inc.'s free cash flow has increased -38.40% from $-40.56M last year to $-24.99M, signaling increasing performance

TG Therapeutics, Inc.'s debt to equity ratio is 1.25, which means that the company's assets are unhealthy financed, signaling financial risk.

TG Therapeutics, Inc.'s debt has increased relative to shareholder equity from 1.14 last year to 1.25 today, signaling weakened financials

TG Therapeutics, Inc. has a net debt to EBITDA ratio of 0.88x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

TG Therapeutics, Inc.'s interest coverage ratio of 3.64 indicates that earnings with good margin can cover interest payments on company debt

TG Therapeutics, Inc.'s profit margin has increased (676.93%) in the last year from 7.11% to 55.22%, signaling increasing performance

TG Therapeutics, Inc.'s short-term assets of $630.76M exceed its short-term liabilities of $153.76M

TG Therapeutics, Inc.'s return on assets of 26.93% is higher than the 5.00% threshold, indicating efficient asset utilization

TG Therapeutics, Inc.'s return on equity of 72.30%, is higher than 15.00%, indicating good performance

TG Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TG Therapeutics, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

TG Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TG Therapeutics, Inc. has negative free cash flow, indicating cash burn

TG Therapeutics, Inc.'s yearly earnings has increased 1.81K% since last year from $23.38M to $447.18M, signaling increasing performance

TG Therapeutics, Inc.'s yearly revenue has increased 87.32% since last year from $329.00M to $616.29M, signaling increasing performance

ROIC 9.93% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

TG Therapeutics, Inc.'s 3-year revenue CAGR of 504.86% is positive, indicating growing revenue over the past 3 years

TG Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

TG Therapeutics, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

TG Therapeutics, Inc. has insufficient data to evaluate this check.

TG Therapeutics, Inc. has an earnings yield of 6.33%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

TG Therapeutics, Inc. is overvalued relative to its fair value price of 4.76 based on EBITDA multiple model

TG Therapeutics, Inc. has an EV/EBITDA ratio of 56.89x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

TG Therapeutics, Inc. is overvalued relative to its fair value price of 8.10 based on Earnings Fair Value model

TG Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

TG Therapeutics, Inc. has a price-to-book ratio of 11.54x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

TG Therapeutics, Inc. has a price-to-sales ratio of 8.72x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue